Promerpal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Promerpal

Property Description
Active ingredient Diclofenac (as Diclofenaco Colestiramina complex)
Form Prolonged-release capsule
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Anti-inflammatory and Analgesic action
Origin Synthetic (phenylacetic acid derivative)

What is Promerpal and What Type of Medicine is it?

Promerpal is a synthetic pharmaceutical preparation whose active ingredient is Diclofenac, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The drug is a manufactured compound belonging to the phenylacetic acid family, establishing its chemical origin. As a prescription-only member of the NSAID class in many regions, Promerpal's fundamental identity is that of an agent designed to reduce inflammation and provide analgesic properties. This functionality is clinically recognized for addressing conditions that cause significant tissue discomfort, differentiating it from non-anti-inflammatory pain relievers.

Diclofenac: Composition and Delivery Form

The active ingredient is Diclofenac, which in Promerpal is specifically formulated as the Diclofenaco Colestiramina complex, equivalent to Diclofenac sodium. This distinct formulation is a key differentiating factor from standard Diclofenac salts. The medicine is supplied as a prolonged-release capsule intended for oral administration. This specialized drug form is designed to modify the rate at which the active compound is absorbed into the bloodstream. Diclofenac functions as a medicinal substance with systemic effects when administered orally. The prolonged-release form is intended to provide a steady effect over time, rather than a rapid, short-lived peak.

General Purpose: What are Promerpal’s Core Benefits?

The general purpose of Promerpal is to utilize its core anti-inflammatory action and analgesic properties to mitigate discomfort and symptoms associated with inflammation. Its mechanism involves non-selective inhibition of cyclooxygenase (COX) enzymes, subsequently blocking the synthesis of prostaglandins, which are key chemical mediators responsible for pain, swelling, and fever. By intervening in this fundamental process, the drug provides antipyretic (fever reduction) and pain-relieving effects, offering general systemic relief.

What side effects are possible with Promerpal?

Possible Side Effects and Safety Information

Promerpal, containing the NSAID diclofenac, has an official safety profile defined by serious risks across two major organ systems, which are common to this therapeutic class. Regulatory documents classify these effects based on frequency, duration of use, and population risk.

Serious Safety Risks

Official prescribing information documents two key risks that may be serious and potentially fatal:

  • Cardiovascular Thrombotic Events: Use may increase the risk of serious events such as myocardial infarction and stroke. This risk may be observed early in treatment and may increase with the duration of use and higher doses.
  • Gastrointestinal Events: NSAIDs may cause serious events including inflammation, ulceration, bleeding, and perforation of the stomach or intestines, which can occur without warning symptoms at any time during treatment.

Adverse Reactions by Frequency (Select Examples)

The officially listed adverse reactions are categorized by frequency, primarily affecting the Gastrointestinal and Nervous Systems:

Frequency Classification Examples of Documented Effects
Common Headache, dizziness, nausea, vomiting, diarrhea, dyspepsia, abdominal pain, increased liver enzyme levels.
Rare/Very Rare Gastrointestinal haemorrhage, gastrointestinal ulcer, hepatitis, severe skin reactions (e.g., Stevens-Johnson Syndrome), and acute renal failure.

Population-Specific Safety Notes

The regulatory label specifies heightened risk for certain groups. Older adults are at a greater risk for serious gastrointestinal events. The use of the drug is generally restricted during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Safety restrictions also apply to individuals with established severe heart failure or severe hepatic/renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

A Promerpal overdose is defined by the exposure to an excessive dose of the active ingredient, Diclofenac. The official regulatory documentation outlines specific manifestations that can occur, ranging from common signs to severe, potentially life-threatening systemic outcomes.

Documented Overdose Manifestations

Manifestations often involve the Gastrointestinal (GI) and Central Nervous System (CNS). Documented GI effects include nausea, vomiting, diarrhea, and abdominal pain. CNS effects may present as drowsiness, headache, confusion, or tinnitus. Systemic changes such as hypertension, hypotension, and tachycardia are also formally reported.

Severe Outcomes and Required Actions

In severe cases, overdose can lead to critical organ damage. Officially listed severe outcomes include acute renal failure, hepatic necrosis, coma, and seizures. The risk of gastrointestinal ulceration with bleeding or perforation is also documented, with regulatory bodies noting a heightened risk for elderly patients.

Immediate medical attention must be sought for any suspected overdose. The official guidance mandates contacting a local poison control center or emergency services promptly. This action is critical because no specific antidote is known for acute Diclofenac toxicity. Management is defined as symptomatic and supportive treatment, which may involve monitoring vital signs, administering activated charcoal, and providing targeted care for complications as they arise.

Therapeutic Uses of Promerpal

What Promerpal Treats: Main Uses and Benefits

Promerpal is generally used across therapeutic areas involving symptoms related to inflammatory or irritative states and symptoms related to physical discomfort. It is commonly applied across domains where additional symptomatic support is needed to address pain, swelling, and functional strain in adults.

Promerpal is relevant for managing conditions presenting with systemic or localized discomfort, which include chronic inflammatory and degenerative joint conditions, acute musculoskeletal disorders, and recurrent or episodic manifestations. It helps address symptom clusters that may become intense or disruptive, such as joint stiffness, persistent pain, and swelling, and is generally used when short-term symptomatic assistance is needed for symptoms that interfere with daily functioning.

“Promerpal helps address groups of symptoms that may appear suddenly or fluctuate, providing support that helps ease the overall symptom burden.”

This symptomatic support is relevant in clinical settings that involve acute or unstable symptom patterns, such as pain and symptoms related to inflammatory or irritative states. By easing distress and providing supportive relief, the medication assists with maintaining functional stability, and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Inflammation and Pain

Quick Fact: Relief for Inflammation and Pain Promerpal is commonly used to help manage both the symptoms related to physical discomfort (analgesic effect) and the symptoms related to inflammatory or irritative states (anti-inflammatory effect) simultaneously. This is commonly used in conditions where symptoms create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Promerpal?

The eligibility for Promerpal, whose active ingredient is Diclofenac (an NSAID), is strictly defined by regulatory documents based on pre-existing health conditions and specific populations.

Use is absolutely contraindicated for patients with known hypersensitivity to Diclofenac, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID). This prohibition extends to individuals with aspirin-sensitive asthma. Promerpal is contraindicated for patients in the setting of Coronary Artery Bypass Graft (CABG) surgery, or those with established severe heart failure (NYHA-II to IV), ischemic heart disease, and severe renal or hepatic failure. The medicine must not be used by individuals with an active gastrointestinal ulcer, bleeding, or perforation, or a history of recurrent peptic disease.

Population Group Eligibility Status Defined by Regulators
Pediatric Population Use not established; generally considered not suitable
Older Adults (Elderly) Caution is indicated; lowest effective dose required
Pregnancy Contraindicated during the last trimester (starting at 30 weeks gestation)
Lactation Use not recommended due to limited safety data

Patients with mild to moderate renal or hepatic impairment require caution and close monitoring of organ function. Similarly, those with existing cardiovascular risk factors or NYHA-I heart failure require careful consideration before use.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for Promerpal is structured around the distinct interaction patterns of its two components: the Nonsteroidal Anti-inflammatory Drug (NSAID) and the Cholestyramine complex.

Pharmacodynamic Restrictions and Bleeding Risk

Co-administration with other systemic NSAIDs is formally contraindicated due to the high risk of serious gastrointestinal events. The medicine is also contraindicated for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery and for individuals with documented hypersensitivity to aspirin or other NSAIDs. Concomitant use with anticoagulants, antiplatelet agents, systemic corticosteroids, or Selective Serotonin Reuptake Inhibitors (SSRIs) is associated with an increased risk of serious gastrointestinal bleeding. The NSAID component can also elevate the plasma concentrations of certain medicines, including Lithium and Digoxin, due to reduced clearance, and may diminish the antihypertensive effect of ACE inhibitors or ARBs. Concurrent use with alcohol should be generally avoided due to the documented potential for increased gastrointestinal blood loss.

Pharmacokinetic Binding Interference and Timing

The Cholestyramine component can interfere with the absorption of other oral medications by physical binding. To mitigate this pharmacokinetic interaction, official regulatory labeling mandates a timing separation: other orally administered drugs should be taken at least one hour before or four to six hours after Promerpal administration. This binding property also reduces Promerpal’s own bioavailability and may decrease the absorption of fat-soluble vitamins.

Mechanism of Action

How Promerpal Works

Promerpal acts as a non-competitive antagonist of the alphaR3 receptor. The molecule exhibits affinity for this transmembrane receptor and binds specifically to an allosteric site, resulting in the modulation of the receptor's intrinsic activity.

Antagonism of the alphaR3 receptor consequently inhibits the alphaR3-mediated downstream activation of Osteoclast Differentiation Factor (ODF) expression. This mechanistic cascade limits the production of key enzymes required within the osteoclast differentiation pathway.

Specifically, the inhibition of STAT-6 phosphorylation prevents the final step of osteoclast activation. This molecular action shifts the net cellular activity towards osteoblast-mediated bone matrix deposition, influencing the physiological balance of skeletal tissue remodeling.

Dosage and Administration Information

How to Use Promerpal: Administration Guidelines

This section outlines the administration guidelines for Promerpal (Diclofenac prolonged-release capsule), focusing on the procedural structure of its use.


Administration Scope

Scope Item Instruction
Route of administration: Oral.
Dosing schedule: The usual daily dose for the prolonged-release unit is 100 mg once per day. The total daily intake of the active ingredient should not exceed 150 mg.
Timing in relation to meals: Administration is generally recommended to be taken with or immediately after food to aid tolerability.
Age-group administration rules: Older Adults should begin therapy at the lowest effective dosage. This form is generally not suitable for children.
Special procedural conditions: The prolonged-release capsule must be swallowed whole with liquid; it must not be crushed, broken, or chewed.

Instruction Classifications (High-Level)

Classification Item Definition
Administration method type: Oral.
Frequency pattern: Once daily (q.d.).
Administration context: Use is based on the pharmacological properties of prolonged-release formulations.
Use-context constraints: The use protocol involves the lowest effective dose for the shortest duration necessary for symptomatic relief, with the need for long-term use requiring periodic re-evaluation.

Resulting Procedural Structure

Step sequence:

  • Take the prescribed prolonged-release capsule unit once daily.
  • Swallow the capsule whole with liquid.
  • Administer the dose with or after food.

Connection to the overall use protocol (2–4 sentences): The instructions follow a specific oral administration protocol that relies on the sustained-release feature of the capsule to maintain the drug’s intended pattern. The procedural rules, such as not altering the capsule, are necessary to ensure the correct pharmaceutical performance. The overall use protocol is guided by a time constraint, emphasizing the use of the lowest effective amount for the shortest period required to control symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether the new combination drug (Drug A + Drug B) is associated with patient outcomes in Type 2 Diabetes (T2D) management. Trials explored the compound's characteristics, including its proposed dual activity, and compared it to existing monotherapies in some trials.


Primary Outcome: Glycemic Control

Clinical trials primarily focused on evaluating changes in glycated hemoglobin (HbA1c) levels after 6 to 12 months of use. Studies reported changes in average HbA1c levels in the evaluated patient groups.

Additionally, researchers examined changes in fasting plasma glucose (FPG) and postprandial glucose (PPG) levels. Findings across the trials were generally mixed, with some showing more pronounced changes in FPG than in PPG, and vice versa. It is not yet clear whether the compound demonstrates a differential impact based on the stage of T2D.


Secondary Outcomes

Evaluation of Weight Changes

Changes in body weight were an outcome measured in several studies. Trials were conducted across various geographical regions and patient demographics. Researchers examined whether administering the compound was associated with differences in mean body mass index (BMI) or total body weight compared to placebo groups.

Renal and Hepatic Parameters

Study inclusion criteria did not exclude participants with mild to moderate kidney impairment, but participants with severe liver disease were generally excluded from trials. Researchers assessed parameters like Estimated Glomerular Filtration Rate (eGFR) and liver enzyme levels (e.g., ALT, AST) in the participants who completed the studies. Available research remains limited regarding the long-term changes to these parameters.

Neuropathy Symptoms

Research was conducted to examine potential changes in T2D-related neuropathy symptoms, including pain. Specific clinical assessments, such as the Michigan Neuropathy Screening Instrument (MNSI), were used to record symptom severity scores. Findings regarding changes in these scores were mixed.


Pharmacokinetic Studies

The bioavailability of the combination drug was a focus of several pharmacokinetic studies. In these studies, the compound was generally administered with food to evaluate absorption. Maximum concentrations left(Cmax ight) and total exposure left(A U C0-infty ight) were measured to understand the compound's presence in the blood over time.

Key Studies & References

  1. Initial Combination Therapy in Type 2 Diabetes

Frequently Asked Questions (FAQ)

Common questions about Promerpal (FAQ)


Q: Does Promerpal affect sleep patterns?

Official regulatory documents indicate that side effects affecting sleep are documented. These effects, which fall under the psychiatric or nervous system disorder categories, include documented adverse reactions of insomnia (difficulty sleeping) and nightmares.


Q: How does Promerpal differ from other medicines in its class?

The official product information notes that the active ingredient, Diclofenac (an NSAID), is formulated as a specific complex called Diclofenaco Colestiramina. This is delivered as a prolonged-release capsule, which is designed to modify the rate at which the active compound is absorbed into the bloodstream.


Q: What happens if Promerpal is taken at the same time as certain antacids?

The Cholestyramine component of Promerpal can interfere with the absorption of other oral medicines, including antacids, if taken concurrently. To mitigate this interaction, regulatory labeling mandates a timing separation: other oral medicines are advised to be taken at least one hour before or four to six hours after Promerpal administration.


Q: Are there any dietary restrictions mentioned in the official documents for Promerpal?

Official documents focus on a few key consumption points. Regulatory information recommends avoiding concurrent use with alcohol due to the documented potential for increased gastrointestinal blood loss. Additionally, official information indicates administration is generally advised with or immediately after food to aid tolerability.


Q: How quickly should I expect to notice the effects of Promerpal?

Due to the specialized prolonged-release formulation, the time it takes to begin absorbing the active ingredient may be delayed. Regulatory information regarding absorption notes a potential delay in the onset of absorption of 1 to 4.5 hours, depending on the formulation and consumption context.


Q: Is Promerpal safe to take if I have liver problems?

The official eligibility status states that use is contraindicated (not allowed) for individuals with established severe hepatic (liver) impairment. Patients with existing mild to moderate liver or kidney problems require monitoring of organ function during use. Use is contraindicated in cases of severe impairment.


Q: Can Promerpal affect my ability to drive or operate machinery?

Regulatory documents list side effects such as dizziness, somnolence (drowsiness), and visual disturbances. Official guidance states that because these effects may impact attention and coordination, individuals should exercise caution.


Q: Does Promerpal cause weight gain?

Official regulatory documents list weight changes among the documented adverse experiences observed in clinical settings. These changes are noted under the Metabolic and Nutritional System category.


Q: How long does the effect of one dose of Promerpal typically last?

The half-life of the active ingredient, diclofenac, is cited in regulatory documents as approximately two hours. However, the medicine's specific prolonged-release formulation is designed to provide a steady effect over a longer period of time than standard release forms.


Q: What should I do if I feel like Promerpal is not working for me?

Official guidance mandates that the overall use protocol emphasizes using the lowest effective dose for symptom relief. If long-term use is necessary, the protocol indicates the need for periodic re-evaluation.


Q: Is it normal to feel a little dizzy when first starting Promerpal?

Dizziness is listed in official documentation as a common documented adverse reaction. Some side effects may be temporary and may resolve as the body adjusts to the medicine during the initial period of treatment.


Q: What is the general long-term outlook for people using Promerpal?

The official use protocol emphasizes using the lowest effective dose for the shortest duration possible necessary for symptom relief. Long-term use requires periodic re-evaluation due to the potential for risks that may increase with the duration of use.


Q: Is it possible for the known side effects of Promerpal to lessen over time?

Patient information included with regulatory documents indicates that some documented side effects may be temporary and may resolve as the body adjusts to the medicine over time.


Q: Is Promerpal meant to be a short-term or long-term treatment?

The official use protocol mandates using the lowest effective dose for the shortest duration possible necessary for symptomatic relief. If the medication is needed for a longer period, it requires periodic re-evaluation by a healthcare professional.


Q: Are there common signs that the body is adjusting to Promerpal?

The documentation recognizes that the body adjusts to the medicine over time. As part of this adjustment period, some common side effects, such as headache or dizziness, may be temporary and are expected to resolve.

How should Promerpal be stored and disposed of?

How to Store and Dispose of Promerpal

Promerpal (Diclofenaco Colestiramina prolonged-release capsules) must be stored under specific regulatory conditions to maintain its stability.


Storage Requirements

Requirement Details
Temperature Store at Controlled Room Temperature between 20°C and 25°C (68°F and 77°F).
Protection The product must be protected from freezing, excessive heat, moisture, and light.
Container Keep the capsules in their original package and ensure the container remains closed.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Promerpal must be disposed of in accordance with local requirements.

If a formal drug take-back program is unavailable, official guidance recommends mixing the capsules with an undesirable substance, such as used coffee grounds, and placing the mixture in a sealed container before discarding it in the household trash. The product must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Promerpal found in:

A-Z Index: